Evidence map›Paper›PMID 42373634›Full record

ArticleNature communications2026

Risk of incident tuberculosis after severe COVID-19: a nationwide cohort study.

Salvador Vargas-García, Lourdes García-García, Christian García, Natalia Vergara, Nadia Escobar, Luis A Villarroel, Kasim Allel, Eduardo A Undurraga, María Elvira Balcells

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Salvador Vargas-GarcíaSchool of Public Health, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID http://orcid.org/0000-0003-1277-0232
Lourdes García-GarcíaCentro de Investigación sobre Enfermedades Infecciosas (CISEI), Instituto Nacional de Salud Pública, Cuernavaca, México.ORCID http://orcid.org/0000-0001-5262-1157
Christian GarcíaPrograma Centro de Salud Pública, Universidad de, Santiago, Chile.
Natalia VergaraDepartment of Epidemiology, Ministry of Health, Santiago, Chile.
Nadia EscobarNational Tuberculosis Control and Elimination Program, Ministry of Health, Santiago, Chile.
Luis A VillarroelInstituto de Ciencias Biomédicas, Universidad Autónoma de Ciudad Juárez, Ciudad Juárez, Chihuahua, México.ORCID http://orcid.org/0000-0001-9603-937X
Kasim AllelSENTINET: Surveillance, Epidemiology, and New Technologies for Infectious Emerging Threats, Santiago, Chile.
Eduardo A UndurragaSENTINET: Surveillance, Epidemiology, and New Technologies for Infectious Emerging Threats, Santiago, Chile. ebalcells@uc.cl.ORCID http://orcid.org/0000-0002-4425-1253
María Elvira BalcellsSENTINET: Surveillance, Epidemiology, and New Technologies for Infectious Emerging Threats, Santiago, Chile. eundurra@uc.cl.ORCID http://orcid.org/0000-0002-7223-9665

Funding

Fondo Nacional de Desarrollo Científico y Tecnológico (National Fund for Scientific and Technological Development) 1211225Fondo Nacional de Desarrollo Científico y Tecnológico (National Fund for Scientific and Technological Development) 1242922Fondo Nacional de Desarrollo Científico y Tecnológico (National Fund for Scientific and Technological Development) 1250853
6 · The paper itself

Abstract

Severe viral infections can disrupt host immunity and increase susceptibility to secondary pathogens. Experimental and preclinical studies suggest that severe viral pneumonia may also trigger reactivation of Mycobacterium tuberculosis infection, yet population-level evidence remains limited. We conducted a nationwide retrospective cohort study in Chile, including more than 3.6 million adults with confirmed SARS-CoV-2 infection, to assess the risk of incident tuberculosis during follow-up. Individuals who developed severe COVID-19 requiring hospitalization had more than an eightfold higher hazard of tuberculosis within one year compared with those with non-severe disease. SARS-CoV-2 vaccination modified this association: the excess risk was substantially greater among unvaccinated individuals, whereas prior vaccination attenuated it. These findings indicate that severe COVID-19 is associated with an increased short- and long-term risk of tuberculosis and support the integration of targeted tuberculosis screening and preventive strategies into post-COVID-19 care, particularly among patients with severe disease.

Indexed as

COVID-19TuberculosisAdultAgedChileCohort StudiesFemaleHospitalizationHumansIncidenceMaleMiddle AgedMycobacterium tuberculosisRetrospective StudiesRisk FactorsSARS-CoV-2

Identifiers

PMID42373634
PMCPMC13458518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.